Friday, 16 October 2026European Markets

IDEX BIOMETRICS Stock Was 10.8% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with IDEX BIOMETRICS (IDEX.OL) rising 10.8% to kr1.73 on Thursday, following the last session's downward trend. Oslo Børs Benchmark Index_GI dropped 0.85% to kr1,236.59, following the last session's downward trend on what was a somewhat down trend exchanging session today.

IDEX BIOMETRICS's last close was kr1.56, 75.89% under its 52-week high of kr6.48.

About IDEX BIOMETRICS

IDEX Biometrics ASA, together with its subsidiaries, designs, develops, and sells fingerprint authentication solutions in Norway, Europe, the Middle East, Africa, the Americas, and the Asia-Pacific regions. The company's fingerprint authentication solutions are used primarily in contactless financial payment, access control, and smart cards, as well as card-based devices for the storage of digital currencies. It primarily serves manufacturers of smart cards for financial payment applications and biometric payment card markets. The company was incorporated in 1996 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, IDEX BIOMETRICS has a trailing twelve months EPS of kr-1.07.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -199.48%.

Yearly Top and Bottom Value

IDEX BIOMETRICS's stock is valued at kr1.73 at 21:32 EST, way under its 52-week high of kr6.48 and higher than its 52-week low of kr1.68.

Volatility

IDEX BIOMETRICS's last week, last month's, and last quarter's current intraday variation average was a negative 3.88%, a negative 2.38%, and a positive 4.45%.

IDEX BIOMETRICS's highest amplitude of average volatility was 7.52% (last week), 4.03% (last month), and 4.45% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.4%, now sitting on 4.72M for the twelve trailing months.

Moving Average

IDEX BIOMETRICS's worth is way below its 50-day moving average of kr2.73 and way under its 200-day moving average of kr3.07.

More news about IDEX BIOMETRICS (IDEX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com